KR20230053549A - 바이러스성 호흡기 감염에 대한 치료 - Google Patents

바이러스성 호흡기 감염에 대한 치료 Download PDF

Info

Publication number
KR20230053549A
KR20230053549A KR1020227044185A KR20227044185A KR20230053549A KR 20230053549 A KR20230053549 A KR 20230053549A KR 1020227044185 A KR1020227044185 A KR 1020227044185A KR 20227044185 A KR20227044185 A KR 20227044185A KR 20230053549 A KR20230053549 A KR 20230053549A
Authority
KR
South Korea
Prior art keywords
antagonist
subject
cells
antibody
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227044185A
Other languages
English (en)
Korean (ko)
Inventor
사이드 무하마드 타히르 나세르
Original Assignee
바이오시리우스 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오시리우스 엘티디 filed Critical 바이오시리우스 엘티디
Publication of KR20230053549A publication Critical patent/KR20230053549A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227044185A 2020-05-19 2021-05-19 바이러스성 호흡기 감염에 대한 치료 Pending KR20230053549A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2007404.3 2020-05-19
GBGB2007404.3A GB202007404D0 (en) 2020-05-19 2020-05-19 Treatment for viral respiratory infections
PCT/GB2021/051207 WO2021234381A1 (en) 2020-05-19 2021-05-19 Treatment for viral respiratory infections

Publications (1)

Publication Number Publication Date
KR20230053549A true KR20230053549A (ko) 2023-04-21

Family

ID=71135334

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227044185A Pending KR20230053549A (ko) 2020-05-19 2021-05-19 바이러스성 호흡기 감염에 대한 치료

Country Status (12)

Country Link
US (1) US20230192838A1 (https=)
EP (1) EP4153302B1 (https=)
JP (1) JP2023526853A (https=)
KR (1) KR20230053549A (https=)
CN (1) CN116406289A (https=)
AU (1) AU2021276614A1 (https=)
CA (1) CA3179461A1 (https=)
ES (1) ES2982939T3 (https=)
GB (1) GB202007404D0 (https=)
HU (1) HUE067327T2 (https=)
PL (1) PL4153302T3 (https=)
WO (1) WO2021234381A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022008973A2 (en) * 2020-07-10 2022-01-13 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
EP1773403B1 (en) 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Alphavirus-based adjuvants
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
MX2013007067A (es) * 2010-12-20 2013-11-01 Medimmune Ltd Anticuerpos anti-il-18 y sus usos.
UA125204C2 (uk) * 2013-09-05 2022-02-02 Аб2 Біо Са Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
US20230173021A1 (en) * 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases

Also Published As

Publication number Publication date
CN116406289A (zh) 2023-07-07
HUE067327T2 (hu) 2024-10-28
AU2021276614A1 (en) 2023-01-05
JP2023526853A (ja) 2023-06-23
GB202007404D0 (en) 2020-07-01
WO2021234381A1 (en) 2021-11-25
PL4153302T3 (pl) 2024-10-07
US20230192838A1 (en) 2023-06-22
EP4153302A1 (en) 2023-03-29
EP4153302B1 (en) 2024-05-29
EP4153302C0 (en) 2024-05-29
CA3179461A1 (en) 2021-11-25
ES2982939T3 (es) 2024-10-21

Similar Documents

Publication Publication Date Title
Sokolowska et al. Immunology of COVID‐19: mechanisms, clinical outcome, diagnostics, and perspectives—a report of the European Academy of Allergy and Clinical Immunology (EAACI)
Halajian et al. Activation of TLR4 by viral glycoproteins: A double-edged sword?
WO2021202563A1 (en) Methods of treating coronavirus infection
KR20210145852A (ko) Il-4r 억제제 투여에 의한 호산구 식도염의 치료법
WO2021211940A1 (en) Methods for treating a complement mediated disorder caused by viruses
KR20130066626A (ko) 항ｃｄ3 면역 분자 요법을 사용하여 간염을 치료하는 방법 및 이를 위한 조성물
BR112021003093A2 (pt) tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta
EP4153302B1 (en) Treatment for viral respiratory infections
WO2023067348A1 (en) Treatment for virally-induced pneumonia
AL-SALIH et al. Identify Human Cluster of differentiation 147 (CD147), a New Target of SARS-CoV-2 Invasion.
JP2023518814A (ja) Ｃｏｖｉｄ－１９肺炎における、ｉｌ－６アンタゴニストに対する応答を予測するためのバイオマーカー
US20240117058A1 (en) Treatment of cytokine release syndrome with gm-csf antagonists
US20230365712A1 (en) Notch4 antibodies and uses thereof
US20160355601A1 (en) Methods and Compositions for the Treatment of Pancreatic Cancer
EP4107186A1 (en) Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
WO2022060412A1 (en) Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
TWI920168B (zh) 調節宿主細胞表面與ｓａｒｓ-ｃｏｖ-２交互作用之方法
US20240025972A1 (en) Methods for modulating host cell surface interactions with sars-cov-2
JP6944701B2 (ja) ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物
US20230416381A1 (en) Methods for treating or preventing acute respiratory distress syndrome
CN115916820A (zh) 用il6拮抗剂治疗包括covid-19肺炎在内的肺炎的方法
WO2025264860A2 (en) Methods of treating post-covid airway disease
KR20130110225A (ko) 인터페론을 사용하여 폐질환을 치료하는 방법
WO2021207667A1 (en) Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
Soeberdt et al. ANTI-INFLAMMATORY EFFECTS OF TRIPEPTIDE WOL074-019 IN MURINE MODELS OF PSORIASIS AND COLITIS

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240516

Comment text: Request for Examination of Application